NCT04269551 - A Safety and Tolerability Study of BIVV020 in Adults With Cold Agglutinin Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 15, 2020

Primary Completion Date

January 6, 2022

Study Completion Date

January 6, 2022

Conditions

Autoimmune Haemolytic Anaemia

Interventions

DRUG

BIVV020

Pharmaceutical form:solution for injection Route of administration: intravenous

Trial Locations (10)

Investigational Site Number :5780001, Bergen

Investigational Site Number :8400006, The Bronx

Investigational Site Number :8400008, Pittsburgh

Investigational Site Number :3800001, Milan

Investigational Site Number :8400002, Fayetteville

Investigational Site Number :2760001, Essen

Investigational Site Number :8400009, St Louis

Investigational Site Number :8400004, Seattle

Investigational Site Number :5280001, Amsterdam

Investigational Site Number :8260001, London

All Listed Sponsors

lead

Bioverativ, a Sanofi company

INDUSTRY